page contents
  • Anne

Sept. 2021 News Updates

Updated: Sep 22

Recent disclosure at the European Society for Medical Oncology (ESMO) 2021: The Phase 3 MONALEESA-2 study, which evaluated Kisqali plus letrozole vs. letrozole alone in postmenopausal women with HR+, HER2- MBC who had not received prior treatment, determined that the median Overall Survival for patients in the combination arm was 63.9 months, vs. 51.4 months on letrozole alone. This represents the longest reported median survival from a randomized trial in HR+/HER2- advanced breast cancer. From:

Another announcement at ESMO 2021 indicated that Enhertu (Trastuzumab Deruxtecan/DS-8201) slashed the risk of disease progression or death by a massive 71.6% over Kadcyla in second-line HER2-positive MBC patients previously treated with Herceptin and chemotherapy. The showing is so impressive that the study authors concluded that the study, called “Destiny-Breast03,” will lead to a paradigm shift in the treatment of HER2-positive breast cancer such that Enhertu will be recommended over Kadcyla as second-line treatment for this patient population. From:

831 views0 comments